Lantheus Holdings, Inc. Accrued Marketing Costs, Current
Lantheus Holdings, Inc. (LNTH) had Accrued Marketing Costs, Current of $36.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Marketing Costs, Current $36.03M.
- 2025-12-31: Accrued Marketing Costs, Current $4.88M.
- 2016-09-30: Accrued Marketing Costs, Current $600.00K.
- 2016-06-30: Accrued Marketing Costs, Current $725.00K.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2026-06-30 | $36.03M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $4.88M 10-Q · filed 2026-08-06 |
| 2016-09-30 | $600.00K 10-Q · filed 2016-11-01 |
| 2016-06-30 | $725.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $572.00K 10-Q · filed 2016-05-03 |
| 2015-12-31 | $490.00K 10-Q · filed 2016-11-01 |
| 2015-09-30 | $970.00K 10-Q · filed 2015-11-04 |
| 2015-06-30 | $1.05M 10-Q · filed 2015-08-05 |
| 2014-12-31 | $978.00K 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |